kaiprazole

Kaiprazole (LP-002) is a novel potassium-competitive acid blocker (P-CAB) being developed by Guangzhou Lupeng Pharmaceutical for the treatment of acid-related disorders, such as duodenal ulcers and gastroesophageal reflux disease (GERD). Unlike traditional proton pump inhibitors (PPIs) that require activation in an acidic environment and bind irreversibly to the H+/K+-ATPase, P-CABs like kaiprazole inhibit the gastric proton pump in a reversible and potassium-competitive manner. This mechanism allows for a faster onset of action, more consistent acid suppression, and a longer duration of effect compared to conventional PPIs. Kaiprazole is currently in Phase 3 clinical development in China for duodenal ulcers and is also being evaluated in Phase 1 studies in combination with other acid-suppressing agents like esomeprazole to assess safety and pharmacokinetics for potential use in refractory acid-related conditions.

Brand names

Anpuzhuo

Other names

Kaiprazole hydrochloride凯普拉唑